Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T11:08:11.763Z Has data issue: false hasContentIssue false
  • English
  • Français

Statins and Cognition: What Can We Learn from Existing Randomized Trials?

Published online by Cambridge University Press:  07 November 2014

Glen L. Xiong ,
Aaron Benson  and
P. Murali Doraiswamy
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Statins are being developed as treatments for Alzheimer's dementia based on evidence from preclinical and observational studies. However, cholesterol plays an integral role in cell membrane signal transduction and suboptimal cholesterol level could potentially impair neuronal function. Additionally, results of observational nonrandomized studies may have been affected by treatment bias.

Methods:

We performed a systematic literature review in MEDLINE from January 1966 to July 2004 and included published prospective, randomized, and placebo-controlled human studies that examined the cognitive effects of statins.

Results:

Nine studies with sample sizes ranging from 22 to 20,000 and duration of 3 weeks to 5 years, met criteria for review. Study populations and cognitive outcomes varied. Four studies were ≥6 months or longer. Overall, none of these studies reported finding a positive benefit for any statin on cognition in non-demented subjects although there was inconsistent evidence for acute cognitive worsening in some studies.

Conclusion:

While statins intuitively have appeal for the prevention or treatment of dementia, any conclusions about their efficacy should await more definitive evidence from on-going prospective clinical trials

Type
Original Research
Information
CNS Spectrums , Volume 10 , Issue 11 , November 2005 , pp. 867 - 875
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Wagstaff, LR, Mitton, MW, Arvik, BM, Doraiswamy, PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871–880.Google Scholar
2.Sparks, DL, Connor, DJ, Browne, PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324–331.Google Scholar
3.Golomb, BA, Criqui, MH, White, H, Dimsdale, JE. Conceptual foundations of the UCSD statin study. Arch Intern Med. 2004;164:153–162.Google Scholar
4.Austen, B, Christodoulou, G, Terry, JE. Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging. 2002;6:377–382.Google ScholarPubMed
5.Casserly, I, Topol, E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139–1146.Google Scholar
6.Kojro, E, Gimpl, G, Lammich, S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase Alzheimer's disease AM 10. Proc Natl Acad Sci U S A. 2001;98:5815–5820.Google Scholar
7.Frears, ER, Stephens, DJ, Walters, CE, Davies, H, Austen, BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999;10:1699–1705.CrossRefGoogle ScholarPubMed
8.Simons, M, Keller, P, De Strooper, B, Beyreuther, K, Dotti, CG, Simons, K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460–6464.Google Scholar
9.Refolo, LM, Malester, B, LaFrancois, J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321–331.CrossRefGoogle Scholar
10.Sparks, DL, Connor, DJ, Browne, PJ, et al. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324–331.Google Scholar
11.Sparks, DL, Martin, TA, Gross, DR, Hunsaker, JC. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000;52:287–290.Google Scholar
12.Sparks, DL, Kuo, YM, Roher, A, et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Ann N Y Acad Sci. 2000;903:335–344.CrossRefGoogle ScholarPubMed
13.Refolo, LM, Pappollo, MA, LaFrancois, J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890–899.Google Scholar
14.Park, IH, Hwang, EM, Hong, HS, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003;24:637–643.Google Scholar
15.Simons, M, Schwarzler, F, Lutjohann, D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebocontrolled, double-blind trial. Ann Neurol. 2002;52:346–350.CrossRefGoogle ScholarPubMed
16.Hoglund, K, Wiklund, O, Vanderstichele, H, et al. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol. 2004;61:333–337.Google Scholar
17.Buxbaum, JD, Cullen, El, Friedhoff, LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decreases the formation of the Alzheimer betaamyloid peptide in vitro and in patients. Frontiers in Bioscience. 2002;7:50–59.Google Scholar
18.Akiyama, H, Barger, S, Barnum, S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421.Google Scholar
19.Pahan, K, Sheikh, FG, Namboodiri, AM, Singh, I. Lovastatin and phyenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophage. J Clin Invest. 1997;100:2671–2679.Google Scholar
20.Bucher, HC, Griffith, LE, Guyatt, GH. Effect of HMGCoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89–95.CrossRefGoogle ScholarPubMed
21.Hebert, P, Gaziano, M, Chan, K, Hennekens, C. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313–321.CrossRefGoogle ScholarPubMed
22.Jick, H, Zornberg, GL, Jick, SS, Seshadri, S, Drachman, DA. Statins and the risk of dementia. Lancet. 2000;356:1627–1631.Google Scholar
23.Wolozin, B, Kellman, W, Ruosseau, P, Celesia, GG, Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439–1443.Google Scholar
24.Rockwood, K, Kirkland, S, Hogan, D, et al. Use of lipid-lowering agents, indication bias, and risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223–227.Google Scholar
25.Yaffe, K, Barrett-Connor, E, Lin, F, Grady, D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;9:378–384.Google Scholar
26.Orsi, A, Sherman, O, Woldesellassie, Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767–769Google Scholar
27.Etminan, M, Gill, S, Samii, A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23:726–730.CrossRefGoogle ScholarPubMed
28.Breitner, JC, Zandi, PP, Li, G, et al. Can statins prevent, AD, or are they just prescribed less often to those with cognitive disorders? Abstract presented at: the Annual Meeting of the International Conference on Alzheimer's Disease and Related Disorders. July 17-22, 2004; Philadelphia, Penn.Google Scholar
29.Li, G, Higdon, R, Kukall, WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624–1628.Google Scholar
30.Zandi, PP, Sparks, DL, Khachaturian, AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217–224.Google Scholar
31.Rea, TD, Breitner, JC, Psaty, BM, et al. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol. 2005;62:1047–1051.CrossRefGoogle ScholarPubMed
32.Doraiswamy, PM, Steffens, D, McQuoid, D. Statin use and hippocampal volume in subjects at risk for Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004;19:275–278.Google Scholar
33.Mason, RP, Herbette, LG, Silverman, DI. Can altering serum cholesterol affect neurologic functions? J Mol Cell Caridiol. 1991;23:1339–1342.Google Scholar
34.Wardel, J, Rogers, P, Judd, P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med. 2000;108:547–553.Google Scholar
35.Zhang, J, Muldoon, MF, McKeown, RE. Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2004;80:291–298.CrossRefGoogle ScholarPubMed
36.Henderson, VW, Guthrie, JR, Dennerstein, L. Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry. 2003;74:1530–1535.Google Scholar
37.Benton, D. Do low cholesterol levels slow mental processing? Psychosom Med. 1995;57:50–53.Google Scholar
38.Botti, RE, Triscari, J, Pan, HY, Zayat, J. concentration of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991;14:256–261.Google Scholar
39.Serajuddin, ATM, Ranadive, SA, Mahoey, EM. Relative lipophilicities, solubilities and structure-pharmacoligical consideration of 3-hydroxy-3methylglutaryl-coenzyme A (reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci. 1991;80:830–834.Google Scholar
40.Vgontzas, AN, Kales, A, Bixler, EO, Manfreidi, RL, Tyson, KL. Effects of pravastatin and lovastatin on sleep efficiency and sleep states. Clin Pharmacol Ther. 1991;50:730–737.CrossRefGoogle Scholar
41.Barth, JD, Kruisbrink, OA, Van Dijk, AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolemia [letter]. Br Med J. 1990;301:669.Google Scholar
42.Schaefer, EJ. HMG-CoA reductase inhibitors for hypercholesterolemia [letter]. N Engl J Med. 1988;19:1222.Google Scholar
43.Roth, T, Richardson, GR, Sullivan, JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426–432.Google Scholar
44.Kostis, JB, Rosen, RC, Wilson, AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989–996.Google Scholar
45.Gengo, F, Cwudzinski, D, Kindel, P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209–214.CrossRefGoogle ScholarPubMed
46.Gibellato, MG, Moore, JL, Selby, K, Bower, EA. Effects of Lovastatin and pravastatin on cognitive function in military aircrew. Av Sp Env Med. 2001;72:805–812.Google Scholar
47.Botti, RE, Triscari, J, Pan, HY, Zayat, J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991;14:256–261.Google Scholar
48.Triscari, J, Karkowitz, JS, McGovern, MW. Pravastatin and lovastatin in cerebrospinal fluid. Clin Neuropharmacol. 1993;16:559–560.Google Scholar
49.Harrison, RW, Ashton, CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clini Pharmacol. 1994;37:231–236.Google Scholar
50.Cutlet, N, Sramek, J, Veroff, A, et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clini Pharmacol. 1995;39:333–336.Google Scholar
51.Muldoon, MF, Barger, SD, Ryan, CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538–546Google Scholar
52. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individual: a randomized placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet. 2002;360:7–22.Google Scholar
53.Shepherd, J, Blauw, GJ, Murphy, MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled tiral. Lancet. 2002(360)1623–1630.Google Scholar
54.Rise, P, Colombo, C, Galli, C. Effects of simvastatin on the metabolism of polyunsaturated fatty acids on glycerolipid, cholesterol, and dev novo lipid synthesis in THP-1 cells. J Lipid Res. 1997;38:1299–1307.Google Scholar
55.Palomaki, A, Malminiemi, K, Metsa-Ketela, T. Enhanced oxidizability of ubiquinol and tocopherol during lovastatin treatment. FEBS Letters. 1997;410:254–258.CrossRefGoogle ScholarPubMed
56.Byington, RP, Davis, BR, Plehn, FJ, et al. Reduction of stroke events with pravastatin: The prospective pravastatin pooling project. Circulation. 2001;103:387–392.Google Scholar
57.Sparks, DL, Sabbgh, M, Connor, DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753–757CrossRefGoogle ScholarPubMed
58.Sparks, DL, Lopez, J, Connor, D, Sabbagh, M, Seward, J, Browne, P. Alzheimer's Disease Cholesterol-Lowering Treatment Team. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT). J Mol Neurosci. 2003;20:407–410.Google Scholar